Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

Overview

This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.

This is a prospective study including patients presenting in aggregate primary lesions affected by nodular BCC of the eyelid (all subjects were submitted to incisional biopsy at 2 mm punch) at the commencement of this study. All were submitted to a local treatment with Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average). All subjects were submitted to a new incisional biopsy at 2 mm punch, after 12 weeks of treatment, and all of them were monitored monthly up to now.If positive biopsy (residue tumor) cases will managed with surgery.

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Central Contacts